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survey from a representative sample of adults from France, Germany, Italy, Spain and 
UK stratified by age and gender. Out of 62,000 respondents, 8,462 (11%) reported a 
diagnosis of depression and 3,937 (6%) having a prescription medication for depres-
sion (Rx). Respondents classified as adherent according to the Morisky Medication 
Adherence Scale (MMAS) were compared to the non-adherent on severity (PHQ-9), 
sociodemographics, health characteristics, health-related quality of life (SF-36), work 
productivity and activity impairment (WPAI) and health care resource use (physi-
cian, hospital and emergency visits). Results: Compared to adherent respondents 
(54%), the non-adherent (46%) were more severe (37% vs. 31% with PHQ-9 score ≥ 15); 
had lower Mental Component Summary (MCS: 32 vs. 33); higher Absenteeism 
(18 vs. 16); more emergency visits in the previous 6 months (0.49 vs. 0.42); and their 
satisfaction with medication was lower (4.97 vs. 5.27) (All p< 0.05). About 75% of 
both groups were participating in psychotherapy at the time of survey and showed 
no significant difference in Physical Component Summary (PCS); Presenteeism; 
and number of hospitalizations. ConClusions: While efficacy measured during 
clinical trials is one of the most influential measures in treatment assessment, 
its ecological validity may be jeopardized by non-adherence to medication in real 
life. The current study shows that low adherence is associated with more severe 
depression, lower treatment satisfaction and lower mental quality of life (MCS) 
in respondents taking antidepressants. These results point at the importance of 
combining adherence and efficacy in the assessment of treatments for depression.
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objeCtives: The objective of our research was to evaluate whether there is a rela-
tionship between patient compliance to blood glucose monitoring (BGM) and HRQoL. 
Moreover we wanted to understand what drives patients not to be compliant to 
BGM. Methods: Data were taken from the ROPER Diabetes program which captures 
information direct from diabetes patients across 27 countries on a regular basis. For 
this specific study data from a sample of 1480 diabetes patients living in the USA 
were collected from June to August 2013. Each patient completed a questionnaire 
comprising some 2000+ variables, which included the EQ-5D-5L instrument and 
accompanying VAS. Patients were asked to state their recommended frequency of 
BGM and what their actual BGM frequency was during the past month. Moreover 
patients were asked to explain why they were not compliant to the recommended 
BGM frequency. Results: Not being compliant explained 52% (R² = 0,52) of the 
variations in HRQoL. The main reasons for not being compliant to the recommended 
BGM frequency were: no coverage of strips by the insurance, pain and discomfort 
related to blood testing, not willing to know the test result. Other less important 
drivers of non-compliance were: inconvenience, issues with food intake and meter 
malfunction. ConClusions: Meter manufacturers are right when they reckon that 
BGM is crucial to diabetes patients’ disease management. Manufacturers have been 
innovating to make the blood testing as convenient as possible. Yet an important 
driver for not complying to the recommended BGM frequency remains to be pain 
and discomfort during blood testing. Manufacturers should also continue their 
efforts to ensure coverage of strips by the different insurance providers in the USA.
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objeCtives: Adherence to antiretroviral therapy (ART) is a critical element towards 
reducing the emergence and spread of drug resistant strains of the virus. To achieve 
a sustained virological suppression, at least a 95% optimal adherence is neces-
sary. This study sought to explore the level of adherence and also identify the fac-
tors contributing to non adherence to therapy among people living with the HIV/
AIDS. Methods: The study was a descriptive cross sectional type. A systematic 
sampling method was used to recruit 146 adult ARV users who have been on therapy 
for at least 3 months and attended the ART clinic between March to May, 2014. 
Using a structured and pretested questionnaire, data on medication adherence 
were collected by adopting a one month visual analogue scale (VAS) recall, a 4 days 
self reported adherence, and a pill identification test technique (PIT). A multivari-
ate logistic regression was then used to determine key factors that were associ-
ated with adherence. Results: Of the three methods used, the optimal adherence 
( ≥ 95%) for the pill identification test (PIT) was 76%, followed by the visual analogue 
scale (71.2%). The 4 days self report recorded the least adherence rate (65.1%). The 
overall rate of high optimal adherence was found to be 51.4%. Respondents aged 
46years or more were highly adherent (61%) than their counterparts who are less 
than 25years (60.0%). Those between 25 to 45years of age were the least adherent 
(45.0%). However, the association between the level of adherence and the socio-
demographic variables (sex, age, employment, and marital status) were not statisti-
cally significant. ConClusions: The overall optimal adherence was found to be 
relatively low and fell below the minimum expected adherence of ≥ 95%. Adherence 
to ART should aim at improving the pre treatment counselling and ensure the avail-
ability of ARV’S at all times.
studies on niCe AssessMents
ni1
exploRing the flAws in CliniCAl dAtA thAt leAd to RejeCtion of  
niCe suBMissions
Hendrich J., Griffiths E.A.
PAREXEL, London, UK
the prediction of these events challenging for primary care management and NHS 
community provision. This could potentially result in increased hospital admissions, 
irrespective of morbidity in the population. Alternatively, the discrepancy may be 
influenced by patient proximity to accident and emergency (A&E).
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objeCtives: To minimize the medical and societal impact of influenza, most WHO 
countries recommend seasonal vaccination in targeted populations; however, lit-
tle is known about the decision-making procedures at a country-level. In Europe, 
the Netherlands has the highest rate of influenza vaccination and France is not far 
behind. Our purpose was to analyze differences and similarities in the information 
used in the decision-making process between these two countries, according to the 
stakeholders involved. Methods: A preliminary documentary analysis identified 
all stakeholders, at national level in both countries, as decision-makers (governmen-
tal authorities), advisors and information providers (research institutions, groups of 
experts), and vaccine manufacturers. We undertook a qualitative study including at 
least one actor from each stakeholder group involved in the process. Thirty-three face-
to-face or telephone semi-structured interviews were conducted during summer 2013 
in France (n= 16), and autumn 2013 in the Netherlands (n= 17). Every interview was 
recorded and transcribed. NVivo10® was used for the qualitative analysis. Results: 
Stakeholders in France and the Netherlands follow international recommenda-
tions. The most relevant information is clinical trials and epidemiological studies. 
Economic models gained importance after the 2009 influenza pandemic, especially 
in the Netherlands. In both countries, the advice of experts is crucial. All types of 
studies are assessed through a standard checklist for public health vaccinations in 
the Netherlands. In France, the assessment is not standardized, but based on general 
checklists. Decision-makers are increasingly worried about the quality of studies, 
due to the lack of standardized methods and influenza uncertainty. When published 
studies are not generalizable, local studies are required. ConClusions: Information 
used in the decision-making process is similar in both countries, although economic 
models have greater importance in the Netherlands. The excellence of the process is 
challenged by the poor quality of influenza data. Efforts should be made on standardi-
zation of study methods, together with harmonization of European policy.
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objeCtives: Poor asthma control in children is partly caused by poor adherence 
to medication. The aim of this study was to investigate the effectiveness and cost-
effectiveness of a Real-Time Medication Monitoring system (RTMM) to improve 
adherence to inhalation corticosteroids. Methods: We performed a multi-center, 
randomized controlled trial. Included were 209 children (< 12 years) with moder-
ate to severe asthma, who had used inhaled corticosteroids (ICS) for at least 3 
months. Patients were followed for 12 months. All children received an RTMM 
device, but only in the intervention group text messages were sent to the parents 
whose child appeared to forget an inhalation. The effectiveness measures were 
adherence (percentage of inhalations taken within the correct timeframe), clini-
cally relevant improvement in asthma control score (ACT, ≥ 3) and asthma-related 
quality of life (PAQLQ, ≥ 0.5) at the end of the study. Costs were calculated from 
a health care perspective (including GP, hospital, medication and RTMM device 
costs) and from a societal perspective (additionally including costs of parents’ 
absence from work). Uncertainty around the point estimates was assessed using 
bootstrapping. Results: Adherence was 73% in the treatment group and 58% in the 
control group (difference 15%-pt, 95%-CIL 8.6%-22.0%). Of the RTMM patients, 33% 
showed clinically relevant improvement in ACT and 22% in PAQLQ. In the control 
group, these numbers were 37% and 38% respectively (differences not statistically 
significant). Costs were higher in the intervention group: € 825 versus € 713, a dif-
ference of € 112 (95%-CI:-€ 139- € 338) from the health care perspective and € 1084 
versus € 845 from a societal perspective (difference 239, 95%-CI: -€ 84 – € 565).The 
incremental costs per 10% improvement from each perspective were € 74 and € 157 
respectively. ConClusions: RTMM increases inhalation adherence, but there is no 
evidence of better health outcomes in this patient population within the first year. 
In these circumstances, this is not a cost-effective intervention.
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objeCtives: Adherence to medication is regarded as an important factor for pre-
dicting clinical outcomes in mental disorders such as depression, bipolar disorder 
or schizophrenia. The current study investigates the relation between adherence 
and the burden of depression on society and individuals. Methods: Data were 
from the 2013 EU National Health and Wellness Survey (NHWS), an internet-based 
